49 results about "Streptococcus pneumoniae" patented technology

The invention relates to the technical field of gene engineering, in particular to a nucleic acid composition, a kit and a detection method for simultaneously and rapidly detecting 16 respiratory tract pathogens. The method specifically comprises the following steps: detecting influenza A virus, influenza B virus, novel coronavirus (ORF1ab gene, N gene), haemophilus influenzae, universal human parainfluenza virus, respiratory syncytial virus, human metapneumovirus, enterovirus, mycoplasma pneumoniae, group A streptococcus, bordetella pertussis, common coronavirus, rhinovirus, bocavirus and adenovirus; a forward primer, a reverse primer and a specific fluorescent probe of streptococcus pneumoniae. Through the PCR reaction, whether respiratory tract pathogens exist or not can be rapidly detected from a specimen at the same time, typing identification of 16 respiratory tract pathogens is carried out at the same time, and compared with a single fluorescent quantitative PCR method, the method is more convenient and rapid, and the cost is lower.

The invention provides a nucleic acid composition for respiratory tract pathogen detection and application thereof, and relates to the technical field of biology. The invention provides a nucleic acid detection composition which has high specificity and can be used for detecting various respiratory pathogens. The composition can be used for detecting influenza B virus, influenza A virus H1N1, influenza A virus H3N2, novel coronavirus N gene, novel coronavirus O gene, respiratory syncytial virus, I-type parainfluenza virus, II-type parainfluenza virus, III-type parainfluenza virus, IV-type parainfluenza virus, rhinovirus, adenovirus, haemophilus influenzae, and the like. The kit has 15 pathogens including streptococcus pneumoniae and staphylococcus aureus, the lower detection limit can be as low as 20 copies / reaction, and the kit plays an important role in rapid detection of respiratory tract pathogens.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which mainly utilizes a multiple fluorescent PCR analysis method to detect related pathogens, so as to simultaneously realize detection of coronavirus, bordetella pertussis, group A streptococcus, parainfluenza virus, streptococcus pneumoniae, haemophilus influenzae and group B streptococcus in a single-tube reaction system. Or detecting and distinguishing at least four of chlamydia pneumoniae. Meanwhile, the detection sensitivity of the composition is higher and reaches 500 copies / mL, and the detection is more accurate.

The invention relates to a plant lactobacillus with hypoglycemic ability, and an application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus plantarum strain Lp116 with the capability of reducing blood sugar, and the preservation number of the lactobacillus plantarum strain Lp116 is CCTCC (China Center for Type Culture Collection) NO: M 20241784. The invention also provides an application of the strain Lp116 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain Lp116. The strain Lp116 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, streptococcus pharyngobuccal inflammation and streptococcus pseudopneumoniae, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention discloses application of chlorinated salicylanilide and a medicine, and relates to the technical field of biology. It is found for the first time that chlorinated salicylanilide not only can well inhibit staphylococcus, streptococcus pneumoniae, klebsiella pneumoniae and other pathogenic bacteria, but also can well inhibit mycobacterium tuberculosis and nontuberculous mycobacterium, so that chlorinated salicylanilide can be used for preparing an inhibitor for pathogenic bacteria. Particularly, the compound can be used for preparing an inhibitor of mycobacterium tuberculosis and / or nontuberculous mycobacterium, and can also be used for preparing a medicine for treating diseases caused by pathogenic bacterium infection.

The invention discloses a cytochalasin compound with wide antibacterial activity as well as a preparation method and application thereof. According to the present invention, the cytochalasin polymer is obtained by separation from the fermentation product derived from the Aspergillus izzukae (Aspergillus izzukae), such that the cytochalasin polymer can be obtained, the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC (China General Microbiological Culture Collection Center) No.40601, and the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC No.40601. The compound has a structure of a cytochalasin mother nucleus and an epiccine mother nucleus, and shows good activity in the aspects of inhibiting or killing staphylococcus aureus, methicillin-resistant staphylococcus aureus, multidrug-resistant staphylococcus aureus, streptococcus pneumoniae, staphylococcus epidermidis and vancomycin-resistant enterococcus faecalis; the compound can be used for preparing novel agricultural or medical antibacterial drugs.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The application discloses a bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and an application thereof, and belongs to the technical field of biotechnology. The bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis is GDMCC No.66556. The metabolic product of the bacillus licheniformis YL-001 provided in the application has the abilities of significantly inhibiting secretion of inflammatory factors and growth of streptococcus pneumoniae and hemolytic streptococcus b, and can improve the total antioxidant capacity of serum. The strain has good biocompatibility and high safety, has important significance for development of anti-inflammatory or antibacterial drugs, health products and food, and is especially suitable for preparation of products with throat-protecting effects.

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

The invention provides a 19F streptococcus pneumoniae invasiveness risk prediction method, and relates to the technical field of molecular biology. Wherein the evaluation marker combination comprises a translation genome, a cell synthesis genome and a ligand transport metabolism genome; the translation genome comprises rluB and rsmE; the cell synthetic genome comprises mscL and murI; and the ligand transport metabolism genome comprises czcD, site B, mtsC and pstS. The evaluation marker combination can accurately evaluate the invasive risk of serotype 19F streptococcus pneumoniae, and realizes molecular typing and risk prediction. The kit has high sensitivity and specificity, is suitable for high-throughput detection, and is helpful for clinical diagnosis and pathogenic mechanism research.

The invention discloses a mixed extract of neem fruit and neem bark, and a preparation method and application thereof, belonging to the technical field of extracts. The preparation method comprises the following steps: S01, pretreatment: crushing and sieving neem fruit and neem bark with a mass ratio of 1: (2-4.5), and mixing to obtain a composite powder; S02, extraction: adding a non-polar solvent to the composite powder, soaking, extracting, and filtering; after the filter residue evaporates the solvent, adding a polar solvent to the filter residue, extracting, filtering, and concentrating to obtain a crude extract; S03, purification: purifying the crude extract with a macroporous adsorption resin, concentrating, and drying. The raw materials for preparing the plant-derived antibacterial agent of the invention are derived from neem fruit and neem bark, which cooperate with each other and have a synergistic effect, and show good antibacterial properties against Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Salmonella typhimurium, Klebsiella pneumoniae and other bacteria.

This invention discloses a strain of *Bacillus saeformis* H1, its culture method, and its applications, relating to the field of microbial technology. The strain was deposited on March 31, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 38117. This strain exhibits strong environmental adaptability, can stably grow under neutral to strongly alkaline conditions, and secretes antibacterial substances with low toxicity and no pathogenicity. After optimization, its optimal liquid fermentation conditions are: 5 g / L yeast extract, 10 g / L peptone, 37 g / L sucrose, pH=10, temperature 25℃, rotation speed 140 rpm, and culture time 24 h. The fermentation supernatant of this strain shows significant inhibitory effects on Gram-positive bacteria such as *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Streptococcus pneumoniae*, and can be prepared into drug sensitivity tablets. The *Bacillus saeformis* H1 provided by this invention can be used to prepare antibacterial drugs or antibacterial infection drugs, providing a new strategy for alleviating the problem of antibiotic resistance.

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a synthesis method of 20-aldehyde-23-piperidinyl-5-O-mycamine glycosyl-tylonolide, its salt and use. The present invention has in vitro antibacterial activity against pathogenic bacteria of livestock and poultry such as Pasteurella multocida, Streptococcus suis, Streptococcus pneumoniae, Staphylococcus aureus, Bordetella bronchiseptica, Klebsiella pneumoniae, Mannheimia hemolytica, Haemophilus parasuis, Actinobacillus pleuropneumoniae, etc., and its antibacterial activity is significantly superior to that of control drugs. The present invention is also superior to macrolide control drugs in antibacterial effect on mycoplasma such as chicken, gallinulina, and pig. It can be used to prepare new high-activity veterinary antibacterial and anti-mycoplasma drugs, and has broad application prospects in livestock and poultry and aquaculture.

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

The invention discloses bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and application of the bacillus licheniformis YL-001, and belongs to the technical field of biology, and the bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis strain is GDMCC (China General Microbiological Culture Collection Center) No.66556. A metabolite of the bacillus licheniformis YL-001 provided by the invention has obvious capabilities of inhibiting secretion of inflammatory factors and inhibiting growth of streptococcus pneumoniae and beta hemolytic streptococcus, and can improve the total antioxidant capacity of serum, and the strain is good in biocompatibility, high in safety and suitable for industrial production. The method has important significance for developing anti-inflammatory or bacteriostatic medicines, health care products and foods, and is particularly suitable for preparing products with the sore-throat relieving effect.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The invention provides a preparation method of a beta-1, 4-N-acetyl glucosamine transferase III mediated sugar chain fixed-point coupling antibody drug conjugate, which comprises the following steps: S1, dissolving an antibody, adding beta-1, 4 galactosidase derived from Streptococcus peumoniae, reacting, and purifying to obtain a G0 glycotype antibody; s2, taking a G0 glycoform antibody, dissolving the G0 glycoform antibody, adding UDP-GlcNAz, Mn < 2 + > and human beta-1, 4-N-acetyl glucosamine transferase III, reacting, and purifying to obtain a glycosylated antibody; s3, dissolving toxin molecules in DMSO (dimethylsulfoxide), adding the dissolved toxin molecules into the linked sugar antibody for reaction, and performing ultrafiltration to obtain ADC molecules; or a one-pot enzyme method is also adopted for preparation. Beta-1, 4-galactosidase of a specific bacterium source is utilized, Beta-1, 4-N-acetyl glucosamine transferase III of a human source is utilized for the first time to prepare ADC, the whole process reaction condition is mild, the needed enzyme is easy to prepare and easy to obtain, and the prepared ADC is good in stability, high in uniformity and good in repeatability.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) a micelle having a shell formed from one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or a combination thereof and having an agent encapsulated within the shell. The methods of the present invention can effectively treat viral infections, such as, for example; severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus, HIV, hepatitis B virus, MERS-CoV, influenza virus, dengue fever virus, respiratory syncytial virus, hepatitis C virus, monkey pox virus, human papilloma virus, methicillin-resistant staphylococcus aureus, pseudomonas, tuberculosis, bacillus anthracis, tetanus, streptococcus pneumoniae, meningococcus, escherichia coli, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, bacillus subtilis, , Legionella genus, Neisseria gonorrhoeae, Neisseria meningitidis, and Salmonella genus.

The invention belongs to the technical field of traditional Chinese medicine extracts, and particularly relates to application of a mulberry leaf extract in preparation of antibacterial products. The mulberry leaf extract can be used for resisting bacteria, is particularly suitable for resisting klebsiella pneumoniae, streptococcus pneumoniae, micrococcus luteus, enterococcus faecium, methicillin-resistant staphylococcus epidermidis, sarcina and acinetobacter baumannii, and has great development potential in research of bacteriostatic drugs, bacteriostatic feed additives and other bacteriostatic products in the future.

The invention belongs to the technical field of microorganisms, and particularly relates to an antiviral and antibacterial composition as well as a preparation method and application thereof. The composition at least comprises the following components: rhizopus oryzae CICC 41440, rhizopus japonicus CICC 41297, a fermentation product of the rhizopus oryzae CICC 41440, a fermentation product of the rhizopus japonicus CICC 41297, and / or an organic solvent extract of the fermentation product of the rhizopus japonicus CICC 41297. Tests prove that the pharmaceutical composition can synergistically inhibit a plurality of pathogens such as rotavirus, streptococcus pneumoniae, adenovirus and klebsiella pneumoniae, meanwhile, the test verifies that the pharmaceutical composition is low in cytotoxicity and high in biological safety, the prevention and treatment level of intestinal diseases and respiratory diseases mediated by the pathogens can be effectively improved, and the pharmaceutical composition is suitable for clinical application. Therefore, the method has good practical application value.

The invention belongs to the field of biological detection. The invention provides a composition for detecting bloodstream infection pathogens based on high-throughput sequencing. Comprising staphylococcus aureus, streptococcus pneumoniae, human herpes B virus type 5, staphylococcus epidermidis, streptococcus agalactiae, orientia tsutsugamushi, coxiella burnetii, chlamydia psittaci, human herpes virus type 2, human herpes virus type 4, human herpes virus type 6, candida tropicalis, enterococcus avium, staphylococcus haemolyticus, streptococcus intermedius and plasmodium vivax. And at least 4 targets in 32 blood flow infection pathogens such as human adenovirus type C, escherichia coli, torque teno virus, corynebacterium striatum and the like. By using the composition disclosed by the invention, a plurality of targets can be amplified and enriched in one tube at the same time, so that the data volume required by subsequent sequencing is remarkably reduced, the analysis work is simplified, and the whole detection is more accurate and efficient.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to an antibacterial small-molecule compound targeting bacterial phospholipid synthetase. The present application provides an antibacterial intervention strategy based on a novel mechanism of action, taking the key enzyme PlsY of bacterial specific membrane phospholipid synthesis as a target, and cracking the cross-resistance problem caused by the concentration of existing antibacterial drug targets. The lead compound T1 obtained by screening has strong inhibitory activity on PlsY, can effectively inhibit pathogenic bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, and has better selective toxicity because the human body has no PlsY homologous protein. The compound has a novel structure and can be optimized, and can be rationally designed through structure-activity relationship, and also has inhibitory effect on plant pathogenic bacteria. The present application opens up a new antibacterial pathway, provides differentiated candidate molecules and reserves for coping with multi-drug resistant infections, and has medical and agricultural potential, and has significant innovation and practicality.

The invention belongs to the technical field of biological detection, and particularly relates to a fluorescence-quenching labeled double-chain universal probe and a mediated amplification method and application thereof. The nucleic acid detection system comprises a fluorescence-quenching labeled double-stranded universal probe, the double-stranded universal probe is composed of two complementary oligonucleotide chains, and the nucleotide sequences of the double-stranded universal probe are shown as SEQ ID NO: 1-4. According to the pathogen nucleic acid detection method based on the universal probe and the target specific anchoring primer, a real-time quantitative PCR or isothermal amplification technology and a fluorescence resonance energy transfer mechanism are integrated, and synchronous and accurate detection of mycoplasma pneumoniae, streptococcus pneumoniae, haemophilus influenzae, influenza A virus, influenza B virus, novel coronavirus and the like is achieved. The method does not need pathogen culture, solves the problems of insufficient specificity, high cost, tedious operation and the like of a traditional detection technology, and can be applied to rapid diagnosis of clinical pathogen infection, reasonable use guidance of antibiotics and epidemiological monitoring.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The invention provides an engineering bacterium for producing vitamin B6 as well as a construction method and application of the engineering bacterium. Specifically, the engineering bacterium contains an exogenous 5 '-phosphopyridoxal synthetase expression cassette, the expression cassette contains a PdxST gene module or a PdxTS gene module, and the PdxST gene module and the PdxTS gene module respectively and independently contain the following genes: a PdxS gene and a PdxT gene; wherein the PdxS gene and the PdxT gene are respectively and independently derived from microorganisms selected from the following group: streptococcus pneumoniae, staphylococcus aureus, bifidobacterium animalis, haematococcus acidilactici, nocoryococcus martensii or a combination thereof. The engineering bacterium greatly improves the production efficiency of the vitamin B6, is suitable for large-scale industrial production, and has great application and popularization values.